NCT05403866View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

August 17, 2022

Primary Completion Date

May 23, 2025

Study Completion Date

May 23, 2025

Conditions
Acute Ischemic Stroke
Interventions
DRUG

LT3001 Drug Product

Administered by intravenous infusion

DRUG

Placebo

Administered by intravenous infusion

Trial Locations (1)

37403

Chattanooga Center for Neurologic Research, Chattanooga

Sponsors
All Listed Sponsors
lead

Lumosa Therapeutics Co., Ltd.

INDUSTRY